CN103784451A - Drug for treating depression - Google Patents
Drug for treating depression Download PDFInfo
- Publication number
- CN103784451A CN103784451A CN201210428565.0A CN201210428565A CN103784451A CN 103784451 A CN103784451 A CN 103784451A CN 201210428565 A CN201210428565 A CN 201210428565A CN 103784451 A CN103784451 A CN 103784451A
- Authority
- CN
- China
- Prior art keywords
- depression
- fluoxetine
- medicine
- drug
- isoxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title abstract description 6
- 229960002464 fluoxetine Drugs 0.000 claims abstract description 11
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims abstract description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 8
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 208000020401 Depressive disease Diseases 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 2
- XPWHRQHBPRSUAW-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-[1-(1,2-oxazol-3-ylmethyl)piperidin-4-yl]imidazol-4-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCN(CC3=NOC=C3)CC2)=N1 XPWHRQHBPRSUAW-UHFFFAOYSA-N 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241001229135 Nassa Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002825 dopamine reuptake Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug for treating depression. The drug contains an effective amount of 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-ylmethyl)piperidine-4-yl]-1H-imidazole-5-yl}pyrimidine-2-amine and an effective amount of fluoxetine, and the mass ratio of 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-ylmethyl)piperidine-4-yl]-1H-imidazole-5-yl}pyrimidine-2-amine to fluoxetine is 3:1 to 6:1. Through combined use of specific drugs, side effects during treatment of depression are greatly reduced, pain of patients is reduced, and recovery of the patients is availed.
Description
Technical field
The present invention relates to a kind of medicine, be specifically related to a kind of medicine of Cure of depression.
Background technology
Depression is a kind of common mood disorders, can be caused by a variety of causes, low as main clinical characteristics take remarkable and lasting mental state, and mental state is low unbecoming with its situation, and suicidal thought and behavior can appear in severe patient.Majority of cases has the tendency of outbreak repeatedly, and the great majority that at every turn show effect can be alleviated, and part can have residual symptoms or transfer to chronic.
Depression has at least 10% patient can occur maniac access, now should be diagnosed as two-phase obstacle.The depression that we often say in addition, refers to major depression (major depression) clinically in fact, has 16% people affected by it in certain period in all one's life in crowd.Suffer from depression except paying serious emotion and social costs, economic cost is also huge.According to World Health Organization's statistics, depression has become the large illness in the world the 4th, expects the year two thousand twenty, may become the second largest disease that is only second to coronary heart disease.
The typical performance of depression clinical symptoms comprises the reduction of three dimension activities: depressed, retardation of thinking, bulesis go down, and other patient can show as main take somatization.Specifically can show as remarkable and lasting depression pessimism, unbecoming with actual environment.The patient that degree is lighter feels depressed, and without happy sense, everything lacks interest, feels " having sense of depression at heart ", " can'ting be happy "; What degree was heavy can be pessimistic desperate, has the sense that one day seems like a year, to live is no better than to die, and patient often tells " the not meaning lives ", " feeling bad " etc. at heart.Climacteric and senile patients with depressive disorder can be with dysphoria, malaise, scorching, flushing hyperhidrosis etc. from head to foot, and child and teenager can show as irritability (as impatient, get angry for some minor matters).Typical depressive mood also has the feature of the light rhythm and pace of moving things at heavy night in morning, depressed comparatively serious in the morning, and can alleviate to some extent at dusk time.
It is blunt that patient may feed back brain response, or memory, aprosexia, and study or ability to work decline or be irresolute, and power shortage, thinks of nothing dry, and adequate Working Life was felt to be unable to cope with now in the past; Patient not only starts self evaluation and reduces, sometimes also all mistakes can be attributed to oneself, normal generation sense of uselessness, nothing are wished sense, helplessness and valueless sense, even start self-accusation from crime, when serious, can occur that delusion of sin (is entangled with and more own little faults repeatedly, think that oneself makes a really big mistake, be about to pay for), repeatedly there is passive idea or behavior.
When a lot of patients do not go on a diet can with appetite decline or hyperfunction, lose weight or (for example increase, in one month, body weight change exceedes 5%), almost have insomnia or hypersomnia every day, also have some patients to there will be hyposexuality, female patient there will be the disorder of menstruation.
The feature of Drug therapy is that onset is relatively very fast, and curative effect is more definite, is suitable for moderate, major depressive disorder patient.Antidepressants are main medicines of the various depressive disorders of current treatment, can efficient solution remove depressive mood and the anxiety of following, anxiety and somatization, effective percentage approximately 60%～80%.
The antidepressant of a current line comprises SSRI class medicine, as paroxetine, Sertraline, fluoxetine, citalopram, fluvoxamine etc., is commonly called as " Five Golden Flowers ", and the reaction of SSRI badness is less and slight, and especially the untoward reaction of anticholinergic and heart is few.That common untoward reaction has is nauseating, vomiting, anorexia, constipation, diarrhoea, xerostomia, tremble, insomnia, anxiety and sexual dysfunction etc.
SNRI class medicine, as venlafaxine, duloxetine, certainly, onset is very fast, has obvious antidepressant and angst resistance effect for SNRI curative effect.Also effective to intractable case.That common adverse reactions has is nauseating, xerostomia, perspiration, weak, anxiety, tremble, sexual impotence and defective ejaculation, when heavy dose of, some patients were blood pressure may slightly raise.
NaSSAs class (NE and specificity 5-HT energy antidepressants), as mirtazapine, there are good antidepressant, anxiety and improve sleep effect, oral absorption is fast, rapid-action, anticholinergic effect is little, has sedation, sexual function is not almost affected, and common adverse reactions is that calmness, drowsiness, dizziness, tired, appetite and body weight increase.
Amfebutamone, the weak inhibitor of norepinephrine, 5-hydroxy tryptamine, dopamine reuptake, does not have inhibitory action to monoamine oxidase, MAO, is applicable to depression and Bipolar Depression, and advantage is little on body weight and sexual function impact.Common untoward reaction has: excitement, xerostomia, insomnia, headache or migraine, feel sick, vomiting, constipation, tremble, hyperhidrosis.
For some anxieties obviously, with the patient of sleep disorder, can short-term use some Benzodiazepineses (stable class) medicine or sleeping medicine that some are novel, as zolpidem, zopiclone.For some serious symptoms, even, with the patient of psychotic symptoms, can merge antipsychotic medications.
But existing medicine is most expensive, and with larger side effect.
Summary of the invention
The object of the present invention is to provide a kind of medicine of Cure of depression, described medicine, by drug combination, in guaranteeing drug effect, significantly reduces side effect.
Technical problem of the present invention solves by following technical solution:
A kind of medicine of Cure of depression, it is characterized in that, described medicine contains effective dose: 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } fluoxetine of pyrimidine-2-amine and effective dose, described 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } pyrimidine-2-amine and fluoxetine mass ratio be 3:1 ~ 6:1.
4-{4-of the present invention (4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } pyrimidine-2-amine and fluoxetine mass ratio, preferably 3.5:1 ~ 5:1, further preferred 4:1.
4-{4-of the present invention (4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } pyrimidine-2-amine and fluoxetine, all the known medical compoundss of affiliated technical field, it can be bought and obtain from market, also can prepare voluntarily by the preparation method disclosing in prior art, the present invention no longer does further restriction with regard to its source with preparation technology.
The present invention is by the use of combining of certain drug, and the side effect while greatly reducing its Cure of depression, has reduced patient's misery, is conducive to patient's recovery.
The specific embodiment
For ease of understanding the present invention, it is as follows that the present invention enumerates embodiment.Those skilled in the art should understand, described embodiment only, for helping to understand the present invention, should not be considered as concrete restriction of the present invention.
Embodiment 1
A kind of medicine of Cure of depression, it is characterized in that, described medicine contains effective dose: 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } fluoxetine of pyrimidine-2-amine and effective dose, described 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } pyrimidine-2-amine and fluoxetine mass ratio be 4:1.
The preparation process of described medicine is the known formulations method of this area, such as blend pelletize etc.
Show by method of testing test known in the art, after patient takes above-mentioned medicament, vomiting and sleep disorder are obviously eliminated, and the side effect while proving this compound medicine to Cure of depression is eliminated obviously.
Applicant's statement, the present invention illustrates detailed process composition and engineering flow process of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned detailed process composition and engineering flow process, do not mean that the present invention must rely on above-mentioned detailed process composition and engineering flow process and could implement.Person of ordinary skill in the field should understand, any improvement in the present invention, and the selections of the equivalence replacement to the each raw material of product of the present invention and the interpolation of auxiliary element, concrete mode etc., within all dropping on protection scope of the present invention and open scope.
Claims (1)
1. the medicine of a Cure of depression, it is characterized in that, described medicine contains effective dose: 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } fluoxetine of pyrimidine-2-amine and effective dose, described 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-base methyl) piperidin-4-yl]-1H-imidazoles-5-yl } pyrimidine-2-amine and fluoxetine mass ratio be 3:1 ~ 6:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428565.0A CN103784451A (en) | 2012-10-31 | 2012-10-31 | Drug for treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428565.0A CN103784451A (en) | 2012-10-31 | 2012-10-31 | Drug for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103784451A true CN103784451A (en) | 2014-05-14 |
Family
ID=50660790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210428565.0A Pending CN103784451A (en) | 2012-10-31 | 2012-10-31 | Drug for treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103784451A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149756A1 (en) * | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| CN106466416A (en) * | 2015-08-20 | 2017-03-01 | 山东金诃药物研究开发有限公司 | Application in preparation medicament for treatment of depression for the compound recipe Rhizoma Gymnadeniae ball |
| WO2017050297A1 (en) * | 2015-09-25 | 2017-03-30 | Sun Jet Biotechnology Inc. | Combination therapy for ev71 infection |
| US12215095B2 (en) | 2018-11-07 | 2025-02-04 | The University Of Melbourne | Compounds for the treatment of respiratory diseases |
-
2012
- 2012-10-31 CN CN201210428565.0A patent/CN103784451A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149756A1 (en) * | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| CN107847480A (en) * | 2015-03-23 | 2018-03-27 | 墨尔本大学 | The treatment of respiratory disease |
| US10722513B2 (en) | 2015-03-23 | 2020-07-28 | The University Of Melbourne | Treatment of respiratory diseases |
| CN107847480B (en) * | 2015-03-23 | 2021-06-25 | 墨尔本大学 | Treatment of Respiratory Diseases |
| US11564925B2 (en) | 2015-03-23 | 2023-01-31 | The University Of Melbourne | Treatment of respiratory diseases |
| US11975005B2 (en) | 2015-03-23 | 2024-05-07 | Tianli Biotech Pty Ltd | Treatment of respiratory diseases |
| CN106466416A (en) * | 2015-08-20 | 2017-03-01 | 山东金诃药物研究开发有限公司 | Application in preparation medicament for treatment of depression for the compound recipe Rhizoma Gymnadeniae ball |
| WO2017050297A1 (en) * | 2015-09-25 | 2017-03-30 | Sun Jet Biotechnology Inc. | Combination therapy for ev71 infection |
| US10548915B2 (en) | 2015-09-25 | 2020-02-04 | Sun Jet Biotechnology Inc. | Combination therapy for EV71 infection |
| US12215095B2 (en) | 2018-11-07 | 2025-02-04 | The University Of Melbourne | Compounds for the treatment of respiratory diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2564187T3 (en) | Glutamate modulation agents in the treatment of mental disorders | |
| JP2025024102A (en) | Neuropathy and methods of treating neuropathies | |
| CN103784451A (en) | Drug for treating depression | |
| WO2022221195A1 (en) | Treatment of essential tremor | |
| JP2019147843A (en) | Fused benzazepines for treatment of stuttering | |
| CN102293301A (en) | Health care tea with hypnosis effect and preparation method | |
| CN107007603A (en) | The method that the illness that sigma-receptor is mediated is treated using Cydic amide derivatives | |
| Avital et al. | Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study | |
| MX2010012146A (en) | 3-hydroxy gepirone for the treatment of attention deficit disorder and sexual dysfunction. | |
| CN101172124B (en) | Novel uses of pennycress, pharmaceutical composition containing the pennycress and preparation method thereof | |
| CN102600277A (en) | Medicine composition containing bacopin extracts | |
| CN105125009A (en) | Healthcare medicinal pillow | |
| CN102317261A (en) | Triple reuptake inhibitors and application method thereof | |
| CN100389780C (en) | Traditional Chinese medicine for treating depressive disorders, and its prepn. method | |
| MX2011011650A (en) | Piperidine derivatives useful for treatment of diebetes. | |
| TWI404542B (en) | Compositions of clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
| CN103908450A (en) | Compound composition for treatment of depression | |
| CN108245512A (en) | Application of isocorynoxeine in preparation of medicine with neuroprotective effect | |
| CN103893303B (en) | External traditional Chinese medicine lotion for treating onychomycosis | |
| CN104491739B (en) | It is a kind of to treat medicine of depression and preparation method thereof | |
| CN103040921A (en) | Pharmaceutical composition for treating constipation | |
| CN104939593A (en) | Health care and health-keeping medicine pillow | |
| CN102949332A (en) | Oral anti-depression slow-release and controlled-release medicinal composition containing citalopram | |
| CN102247407B (en) | Chinese medicinal composition for treating ischemic stroke including hemiplegia caused by cerebral thrombosis | |
| CN103933339A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140514 |